Skip to content

Sample Page

Author: BioXcel Therapeutics

Posted Date:

May 28, 2026

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

BioXcel Therapeutics

May 28, 2026
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

BioXcel Therapeutics

May 15, 2026
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

BioXcel Therapeutics

April 17, 2026
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

BioXcel Therapeutics

April 8, 2026
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

BioXcel Therapeutics

April 8, 2026
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

BioXcel Therapeutics

April 1, 2026
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

BioXcel Therapeutics

April 1, 2026
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting

BioXcel Therapeutics

March 27, 2026
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

BioXcel Therapeutics

March 12, 2026
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

BioXcel Therapeutics

March 12, 2026

1 2